Articles tagged with Vaccine Development
Georgia Tech researchers have developed a trivalent vaccine that offers broad protection against not only SARS-CoV-2 variants but also other bat sarbecoviruses. The groundbreaking vaccine has shown complete protection with no trace of virus in the lungs, marking a significant step toward a universal vaccine for coronaviruses.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
A new study by Karolinska Institutet researchers has identified the protein on cell surfaces that the Crimean-Congo hemorrhagic fever virus uses to enter human cells. This discovery is crucial in developing effective treatments and vaccines for the deadly disease, which can cause up to 40% mortality rate.
Low HPV vaccine uptake among US adults aged 27-45 is a concern, particularly for men and Hispanic individuals. Experts stress the need to address disparities in vaccination rates to prevent cancer cases.
Developed by scientists from the University of Oxford, the LungVax vaccine uses technology similar to the highly successful Oxford/AstraZeneca COVID-19 vaccine. The vaccine will train the immune system to recognise and attack abnormal lung cells with neoantigens.
A new vaccine developed by UCLA researchers demonstrates high protection against melioidosis, a tropical disease that causes 89,000 fatalities annually. The vaccine was tested in mice and found effective even against a highly lethal strain of the bacteria.
Scientists identified key factors in developing long-lasting immunity against dengue virus through analyzing immune responses to natural infection and vaccines. The study revealed molecular markers that could be used in novel vaccine development.
Researchers found that early antibiotic treatment accelerated recovery in COVID-19 patients. The study used a combination of antibiotics, including amoxicillin and rifaximin, within the first three days of infection. This treatment significantly reduced the risk of long-term COVID symptoms.
A new multitasking substance has been identified to prevent and treat both flu and COVID-19 infections concurrently. The long-acting recombinant cytokine protein rhIL-7-hyFc demonstrated therapeutic and preventive effects against various respiratory diseases, including COVID-19, influenza virus, and respiratory syncytial virus.
A competition among researchers predicted B. pertussis vaccine responses based on a simple correlation between calendar age and antibody responses. The result highlights the need for further research to understand variability in vaccination outcomes.
Researchers developed a protein-based vaccine candidate called SpyCage that induces an immune response in rodent models, clearing COVID-19 infections more quickly than controls. The platform has the potential to prevent infection and transmission of respiratory viruses like SARS-CoV-2 by inducing a mucosal immune response.
A new study finds that the high burden of typhoid fever in sub-Saharan African countries calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines. The study estimates that there are 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths.
Researchers developed an AI framework that combines dimension reduction techniques with a new clustering algorithm to quickly identify groups of viral genomes at risk. This enables proactive response measures like tailored vaccine development, potentially eliminating emerging variants before they spread.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
Researchers identified a mechanism of 'copy-paste' genetics in Plasmodium falciparum that increases genetic diversity of surface proteins, potentially evading the human immune system. This discovery offers valuable insights for vaccine design and could help inform new approaches to preventing malaria.
Researchers at MIT have developed a new type of nanoparticle that can both deliver vaccines and act as an adjuvant to generate a strong immune response. The particles, called metal-organic frameworks (MOFs), were shown to be effective in delivering the SARS-CoV-2 spike protein and boosting the immune system's response.
A Zika vaccine candidate has been shown to be safe and effective when administered both before and during pregnancy, according to a new study. The purified, inactivated vaccine (ZPIV) candidate prevented placental damage and blocked transmission of Zika virus from mother to fetus.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
Researchers developed a new recombinant flu vaccine called Hexaplex, which provided superior protection against H1N1 and H3N2 viruses in animal models. The vaccine's combination of six proteins from different groups resulted in strong antibody production and T-cell activation, offering broader immunity.
A new approach to fighting HIV has been developed using RNA, specifically small interfering RNAs (siRNA), which regulate gene expression in cells. This nanomedicine was shown to reduce HIV replication by 73% and is intended for vaginal application to prevent sexual transmission.
Scientists used Delta's GPU-based architecture to study the life cycle of the Hepatitis B virus, revealing how it binds human proteins called importins. The research provides a platform for developing inhibitors that could block this interaction and prevent the virus from accessing the nucleus.
Researchers at Texas A&M discovered that immune genes are frequently exchanged between Myotis bat species during seasonal mating swarms, potentially helping humans fight emerging diseases. The study's findings have opened new questions about the importance of hybridization in evolution and its impact on genomicists' knowledge.
A new study from Uppsala University found that people who have had herpes virus are twice as likely to develop dementia as those who have never been infected. The researchers studied 1,000 70-year-olds over 15 years and confirmed previous research on the potential link between herpes and dementia.
Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering have made significant breakthroughs in understanding how antibodies combat herpes simplex virus (HSV) infections. The study reveals that antibody effector functions play a critical role in protecting against HSV, which may lead to new treatments for n...
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
The Butantan-DV vaccine has been shown to be effective in preventing dengue development in 79.6% of vaccinated individuals, regardless of age group or prior exposure history. The vaccine also demonstrated safety for all participants, with mild to moderate side effects reported.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
Scientists have successfully replicated QS-21, a potent vaccine adjuvant, in an alternative plant host for the first time. This breakthrough enables the production of this highly valued compound in a more sustainable manner.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
A single dose of the typhoid conjugate vaccine provided lasting protection against typhoid fever in over 28,000 healthy children in Malawi. The vaccine efficacy remained strong over four years, with a 78.3% efficacy rate and one case prevented for every 163 children vaccinated.
A subset of CD4+ 'helper' T cells helps fight cytomegalovirus infection and reduces the chances of transmission. The late-rising T cells expand long after the initial response has died down, gathering in high numbers in the salivary gland.
A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
A University of Alberta-led international network is studying very rare adverse events after vaccination, using cutting-edge techniques and unprecedented data from around the world. The goal is to enhance vaccine safety assessment and inform health authorities on the most appropriate type of vaccine for specific outbreak settings.
Researchers at UC San Diego School of Medicine found that the immune system's response to Staphylococcus aureus bacteria can be tricked into producing non-protective antibodies, making vaccines ineffective. The study suggests targeting subdominant antigens for future vaccine development.
Researchers are exploring 'priming, shaping, and polishing' techniques to develop an HIV vaccine targeting rare immune cells that produce broad-neutralizing antibodies. The Amsterdam UMC-led project aims to create an effective vaccine for low- and middle-income countries with a €4.5m grant.
A new study suggests a universal coronavirus vaccine could have saved millions of lives and prevented suffering by offering some degree of protection against a range of strains. The study found that having a universal vaccine at the start of the pandemic would have been cost-saving even with low efficacy rates.
A Swedish study found that up to 7% of blood donors had a history of TBE virus infection, affecting over 160,000 people. Vaccination coverage was estimated at 8-57% across different regions.
Researchers from Binghamton University are unraveling the workings of Group B Strep (GBS) infections, which could someday lead to a vaccine. They have identified a novel protein that could serve as a vaccine candidate to fight this bacterium, impacting women's reproductive health and neonatal outcomes.
Researchers have developed a novel tool for the selective and efficient recovery of large DNA molecules using TAR cloning. This technique has been applied to isolate individual gene alleles, study genome architecture and evolution, and engineer synthetic viruses with novel properties, including vaccine development.
Researchers have identified a novel class of antibodies capable of neutralizing both certain H3 and H1 strains of the flu virus, with potential applications in developing more broadly protective flu vaccines. The findings could also contribute to reducing reliance on chicken egg-based manufacturing methods.
Researchers have developed a new method for identifying epitopes that promise safe immunization across broad populations, enabling the creation of targeted vaccines. By exploiting epitope overlaps, they were able to integrate significantly more epitopes into their vaccine candidates, covering over 98% of the world population.
Scientists in Germany developed a new analytical method to precisely elucidate the size of particles, structure, and RNA molecules in pharmaceutical products. This information can help evaluate product quality, enabling improved development of new products.
Researchers at the University of New Mexico have developed a new vaccine that can lower LDL cholesterol levels by up to 30% and reduce the risk of heart disease. The vaccine is based on a non-infectious virus particle and has shown promising results in animal trials.
A study by researchers at the Medical University of Vienna found that natural killer cells may play a crucial role in protecting against multiple sclerosis (MS) disease. The investigation revealed that strong EBV-specific and autoreactive immune responses combined with poor autoimmunity control increase MS risk.
Researchers have created a single-dose, dry-powder inhalable vaccine platform that induces broad-spectrum immune responses and expands vaccine protection. The platform's nano-micro composite structure enables efficient delivery to the lungs, promoting long-lasting immunity with just one inhalation.
Two Melbourne-made COVID-19 vaccines demonstrated strong boosting capabilities against SARS-CoV-2 variants in a Phase 1 clinical trial. The vaccines focus the immune response on the receptor binding domain, potentially providing a more efficient approach to boost immunity.
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
Researchers at the University of Toronto have discovered a novel ionizable lipid nanoparticle that enables efficient muscle-focused mRNA delivery while minimizing off-target effects. The study demonstrates potent cellular immune responses and potential as a viable candidate for cancer vaccine development.
The European Union has approved vaccines for pregnant women and monoclonal antibodies to prevent respiratory syncytial virus (RSV) among young children. New sequencing tools have also been developed to track the genetic diversity of RSV and inform vaccine effectiveness and treatment strategies.
Researchers have identified a sequence within therapeutic mRNAs that causes unintended immune responses and found a way to correct these errors. By designing 'slip-resistant' mRNAs, the team aims to produce future mRNA vaccines with improved safety and efficacy.
Researchers developed GraphNovo, a program that provides accurate understanding of peptide sequences in cells, improving immunotherapy for unique cases. The AI model enhances de novo peptide sequencing accuracy, filling gaps with precise mass data.
Researchers at Osaka Metropolitan University have successfully developed a novel pneumococcal vaccine that demonstrates efficacy in suppressing pneumococcal pneumonia in macaques. The vaccine's design combines proprietary mucosal vaccine technology with pneumococcal surface proteins to cover a wide range of serotypes.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
A team of researchers developed a vaccine that stimulates regulatory T cells to suppress harmful immune cells, prolonging allograft survival in mice. This discovery identifies an analogous pathway in humans, suggesting potential treatment for autoimmune disorders and organ transplant patients.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
Researchers found that antibodies targeting the N-terminal domain have a lower ability to protect against delta variants compared to those targeting the receptor-binding domain. The study provides new insights into vaccine development, highlighting the importance of understanding antibody responses.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
The UK has launched four new research hubs to address challenges of vaccine manufacturing and delivery in developing countries. The hubs will use lessons from the global COVID-19 rollout to improve processes, with funding from £33 million UK aid and £1.5 million EPSRC co-funding.